Tri Locum Partners LP Lowers Stock Position in argenex SE $ARGX

Tri Locum Partners LP decreased its holdings in shares of argenex SE (NASDAQ:ARGX) by 16.0% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 31,635 shares of the company’s stock after selling 6,018 shares during the period. argenex makes up about 3.2% of Tri Locum Partners LP’s holdings, making the stock its 13th biggest position. Tri Locum Partners LP’s holdings in argenex were worth $23,101,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. M&T Bank Corp lifted its holdings in shares of argenex by 20,977.7% in the 4th quarter. M&T Bank Corp now owns 778,610 shares of the company’s stock valued at $654,772,000 after buying an additional 774,916 shares during the period. Sands Capital Management LLC grew its holdings in argenex by 2,046.6% during the fourth quarter. Sands Capital Management LLC now owns 356,870 shares of the company’s stock worth $300,110,000 after acquiring an additional 340,245 shares during the period. Invesco Ltd. grew its holdings in argenex by 390.4% during the fourth quarter. Invesco Ltd. now owns 416,408 shares of the company’s stock worth $350,178,000 after acquiring an additional 331,489 shares during the period. Wellington Management Group LLP raised its position in argenex by 80.1% in the third quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock worth $538,408,000 after acquiring an additional 324,653 shares in the last quarter. Finally, Two Sigma Investments LP raised its position in argenex by 570.3% in the third quarter. Two Sigma Investments LP now owns 294,160 shares of the company’s stock worth $216,961,000 after acquiring an additional 250,278 shares in the last quarter. 60.32% of the stock is owned by hedge funds and other institutional investors.

argenex Price Performance

NASDAQ:ARGX opened at $882.56 on Thursday. The firm has a 50 day simple moving average of $873.58 and a 200-day simple moving average of $816.78. The firm has a market cap of $55.21 billion, a PE ratio of 33.89, a P/E/G ratio of 1.13 and a beta of 0.45. argenex SE has a 1-year low of $596.01 and a 1-year high of $953.58.

argenex (NASDAQ:ARGX) last released its earnings results on Tuesday, July 21st. The company reported $7.32 EPS for the quarter, beating the consensus estimate of $5.86 by $1.46. argenex had a return on equity of 43.59% and a net margin of 32.19%.The firm had revenue of $1.54 billion during the quarter, compared to analyst estimates of $1.45 billion. As a group, sell-side analysts expect that argenex SE will post 27.38 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on ARGX shares. Wedbush boosted their target price on shares of argenex from $1,000.00 to $1,050.00 and gave the stock an “outperform” rating in a research report on Tuesday. Guggenheim raised their price objective on shares of argenex from $1,135.00 to $1,185.00 and gave the company a “buy” rating in a research note on Friday, July 24th. Citizens Jmp lowered their target price on shares of argenex from $944.00 to $932.00 and set a “market outperform” rating on the stock in a research report on Friday, July 24th. Citigroup increased their target price on shares of argenex from $1,152.00 to $1,182.00 and gave the company a “buy” rating in a report on Tuesday, July 21st. Finally, Wells Fargo & Company boosted their price target on argenex from $1,260.00 to $1,291.00 and gave the stock an “overweight” rating in a research note on Monday, June 1st. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $1,056.89.

Key argenex News

Here are the key news stories impacting argenex this week:

• Positive Sentiment: Forte Biosciences acquisition expands the autoimmune pipeline: argenx agreed to acquire Forte for approximately $2.2 billion, or $77 per Forte share in cash. The transaction would add Forte’s autoimmune drug candidate to argenx’s portfolio and could strengthen its long-term growth opportunities. Argenx signs agreement to buy Forte Biosciences for $2.2bn
• Positive Sentiment: Analysts raised their targets: Wedbush lifted its price target from $1,000 to $1,050 and assigned an “Outperform” rating. A separate Seeking Alpha analysis upgraded ARGX to “Buy” with a $1,050 target, citing continued VYVGART growth, additional label expansions, at-home administration and pipeline potential. Wedbush raises argenx price target argenx: Upgrading To Buy, The VYVGART Growth Cycle Has Further To Go
• Positive Sentiment: Long-term earnings expectations improved: HC Wainwright maintained a “Buy” rating and raised its EPS forecasts for 2026 through 2030, including increases to $34.38 for 2027, $43.50 for 2028, $53.47 for 2029 and $64.39 for 2030. The revisions indicate stronger expected VYVGART-driven growth and pipeline contributions. HC Wainwright earnings estimate changes
• Neutral Sentiment: Relative performance remains in focus: Zacks compared argenx’s year-to-date performance with Agilent Technologies and the broader medical sector, but the report did not identify a new fundamental catalyst. Is Argenx Outperforming Other Medical Stocks This Year?
• Negative Sentiment: Deal scrutiny and valuation risks: A law firm is investigating whether Forte shareholders are receiving adequate consideration and whether the sale process was appropriate. Separately, analyses suggested ARGX could be fairly valued or as much as 15% above fair value after the Forte deal, raising concerns about acquisition execution and limited near-term upside. Forte Biosciences investor alert argenx could be 15% above fair value

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.